NCT05802394

The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Peking Union Medical College Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in borderline resectable or locally advanced pancreatic cancer. The main questions it aims to answer are: * prognostic value of baseline MRD; * the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood derived from participants will be obtained for MRD test before conversion therapy initiation and at the first imaging assessment after chemotherapy.

Conditions

• Pancreatic Cancer
• Locally Advanced

Interventions

Type	Name	Description
DRUG	Later-line therapy	Another chemotherapy regimen, targeted therapy, or immunotherapy

Timeline

• Start date: 2023-02-01
• Primary completion: 2026-02-01
• Completion: 2030-02-01
• First posted: 2023-04-06
• Last updated: 2023-04-12

Locations

1 site across 1 country: China